Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Alodase** is a Wellmed Pharma branded fixed-dose oral tablet containing aceclofenac 100 mg, paracetamol 325 mg, and serratiopeptidase 15 mg. Aceclofenac is a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase-mediated prostaglandin synthesis; paracetamol provides analgesic and antipyretic activity through incompletely resolved, predominantly central mechanisms that include cyclooxygenase-pathway modulation; and serratiopeptidase is a proteolytic enzyme used for anti-inflammatory and anti-edema effects. The product is marketed for pain and inflammation, including musculoskeletal pain and postoperative inflammatory swelling. ([wellmedpharma.com](https://www.wellmedpharma.com/product/alodase/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Alodase.